The long-term outcomes of palliative operations and diagnostic laparotomies in 98 patients with radically inoperable cancers of gastric-intestinal tract are analysed. Increased blood oncoantigene parameters are not to be considered as subclinical markers of oncological process. Though complex assessment of cancer patients' curability the parameters of oncoantigene content may occur to be useful in determination of the prognosis of life longitude of patients having undergone the primary tumour focus removal.
Download full-text PDF |
Source |
|---|
Publication Analysis
Top Keywords
Similar Publications
An Independent Validation Study of Candidate microRNAs as Predictive Biomarkers for Bevacizumab-based Therapy in Patients With Metastatic Colorectal Cancer.
In Vivo
August 2021
Department of Comprehensive Cancer Care, Masaryk Memorial Cancer Institute, Brno, Czech Republic;
Background/aim: The monoclonal antibody bevacizumab is a standard drug used in combination with oxaliplatin (FOLFOX) or irinotecan (FOLFIRI) based chemotherapy in the first or second-line treatment of metastatic colorectal cancer (mCRC). Our previous study identified and subsequently validated 4 microRNAs in a small group of patients as predictors of the therapeutic response to bevacizumab combined with chemotherapy. The aim of this follow-up study is to confirm the predictive ability of these tissue miRNAs in a larger independent cohort of mCRC patients.
View Article and Find Full Text PDFRandomized phase II trial of S-1 plus cisplatin or docetaxel plus cisplatin with concurrent thoracic radiotherapy for inoperable stage III non-small cell lung cancer.
Cancer Med
January 2021
Department of Respiratory Medicine, Yokohama Municipal Citizen's Hospital, Kanagawa, Japan.
Cisplatin-based chemoradiotherapy is considered standard treatment for unresectable locally advanced non-small-cell lung cancer (LA-NSCLC). This study examined two regimens of chemotherapy in concurrent chemoradiation. Eligible patients with unresectable, radically irradible LA-NSCLC were randomized to either the SP (S-1 and cisplatin) or DP (docetaxel and cisplatin) arms with concurrent thoracic radiotherapy of 60 Gy, comprising 2 Gy per daily fraction.
View Article and Find Full Text PDFNon-operative management for oral cavity carcinoma: Definitive radiation therapy as a potential alternative treatment approach.
Radiother Oncol
January 2021
Department of Radiation Oncology, Princess Margaret Cancer Centre, University of Toronto, Canada. Electronic address:
Purpose: To determine the outcomes of oral cavity squamous cell cancer (OSCC) patients treated with non-surgical approach i.e. definitive intensity-modulated radiation therapy (IMRT).
View Article and Find Full Text PDFConsensus on Stereotactic Body Radiation Therapy for Small-Sized Hepatocellular Carcinoma at the 7th Asia-Pacific Primary Liver Cancer Expert Meeting.
Liver Cancer
November 2017
Department of Radiation Oncology, Zhongshan Hospital, Fudan University, Shanghai, China.
Background: Stereotactic body radiation therapy (SBRT) is an advanced technique of external beam radiation therapy that delivers large ablative doses of radiation. In the past decade, many cancer centers have adopted SBRT as one mode of radically treating small-sized hepatocellular carcinoma (HCC), based on encouraging clinical outcomes. SBRT thus seems reasonable as first-line treatment of inoperable HCC confined to the liver.
View Article and Find Full Text PDFIntroduction: Pancreatic cancer (PDAC) is one of the most aggressive malignancies. Its poor prognosis is due to a combination of various factors, mainly aggressive biology of the tumour, non-specific symptoms in early stages, their underestimation, prolonged time to diagnosis and late onset of treatment. The majority of patients are diagnosed in an advanced stage of the disease.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!